Navigation Links
Genentech Purchases Arrayit Technology
Date:9/10/2013

SUNNYVALE, Calif., Sept. 10, 2013 /PRNewswire/ -- Arrayit Corporation (OTCQB: ARYC) reports that pharmaceutical giant Genentech has purchased Arrayit's patented technology to accelerate drug discovery.

Genentech purchased Arrayit's NanoPrint™ LM60 Microarrayer Platform including a manufacturing robot, printing pins and consumables for $138,000. Genentech's pioneering research using ARYC technology was published in the April 2013 edition of "Current Protocols in Protein Science" by Genentech scientists Dr. Irene Tom, Dr. Nicholas Lewin‐Koh, Dr. Sree R. Ramani and Dr. Lino C. Gonzalez in the Department of Protein Chemistry, Genentech, in South San Francisco, California USA. The scientific publication is available on-line using the link: http://www.currentprotocols.com/WileyCDA/CPUnit/refId-ps2703.html

Genentech scientists employ Arrayit protein microarray technology to screen protein-protein interactions in a massively parallel manner as a means of speeding the discovery of new protein drugs. Genentech's authors emphasize that "Functional protein microarrays offer the capability for high-throughput protein interaction analysis and have long promised to be a powerful tool for understanding protein interactions at the proteome scale."

Proteins are the molecules encoded by cellular genes, and the approximately 25,000 genes in the human genome encode all of the known proteins in the human body, which is known as the human proteome. Proteins possess significant therapeutic value, as emphasized by Genentech's blockbuster protein drugs Rituxan, Avastin and Herceptin, which have combined annual sales of approximately $7.8B. Genentech was acquired by Roche in 2009 for $46.8B and operates as a member of the Roche Group.

List of other Arrayit Corp Customers

Government Laboratories

Centers for Disease Control

Veterans Administration Medical Center

SAIC

West Point Military Academy

Sandia National Laboratory

Commonwealth Scientific and Industrial Research Organization (CSIRO)

Infectious Disease Research Institute

National Institutes of Health

Virginia Biosciences Community

Lawrence Berkeley National Laboratory

Pharma/Diagnostics

Genesis Diagnostics Ltd

Excelsior Bio-Systems Inc

Eventus Dx

Progenika Biopharma

Belmedtechnika

Ibis Bioscience/Abbott Laboratories

Opko Pharma

Baxter Healthcare

Natrix Lab

Perkin Elmer Life Sciences

Life Science/Biotech

European Biotech Network

VWR International

SIC Vita S

Wallac Oy

Molecular Devices UK Ltd.

Gene Company

ChemBio

Polgen

Research Biolabs Pte Ltd

Digilab

University Laboratories

University of Texas Southwestern Medical Center

University of Illinois

Monash University

University of Oklahoma

University of California, Davis

Arizona State University

Stanford University

University of Arizona

University of California, San Diego

Texas Tech

About Arrayit Corporation                           

Arrayit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company's innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. Arrayit's products are used by nearly every major research center in the world.

About Liston Street Pulse                                                

Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Subscribe here to read more about ARYC, including CEO interviews.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2012 and Form 10-Q for the fiscal first quarter ended March 31, 2013, Form 10-Q for the fiscal second quarter ended June 30, 2013.

Sources:

www.arrayit.com
www.listonstreetpulse.com


'/>"/>
SOURCE Arrayit Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
2. PDL Files for Arbitration Against Genentech Based on Underpayment of Royalties
3. RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
4. Statement from Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on the Front Page New York Times Story Regarding the Pre-emptive Strikes of Amgen/Genentech to Restrict Access to Affordable and Safe Biosimilars
5. Afraxis Grants Exclusive Global License to Genentech
6. Roswell Park Cancer Institute Purchases Six Ion Torrent Sequencers
7. Genomic Research Service Provider DNA Link Purchases 10 Ion Proton Sequencers
8. Arrayit on Major Fundraising Drive
9. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
10. TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
11. Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 Shire plc ... Jeff Poulton , Chief Financial Officer, will present at the ... Boston, MA on Wednesday, May 04, 2016, 10:00 ... will be available on the Presentations and Webcasts section of ... of the webcast will be available on this same website ...
(Date:4/27/2016)... 27, 2016 Oasmia Pharmaceutical ... of a new generation of drugs within human ... results for Paclical/Apealea in the Phase III study ... epithelial ovarian cancer. These preliminary results showed non-inferiority ... with carboplatin versus Taxol in combination with carboplatin. ...
(Date:4/27/2016)... 2016 The global  gamma ... billion by 2022, according to a new report ... towards a healthy lifestyle is expected to drive ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... health treatment expenditure has urged consumers to switch ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Create an ... users can distort and manipulate three-dimensional shapes with ease all within Apple ... point, lines, polygons, polygon texture animation, opacity texture animation, overall shape texture displacement, ...
(Date:4/30/2016)... , ... April 30, 2016 , ... ... announced RANKED Health , a program to critically evaluate and rank health-focused ... of the program is to provide independent, unbiased and accurate information to help ...
(Date:4/30/2016)... ... April 30, 2016 , ... Dr. Trevor ... of EMED, today signed a multifaceted agreement which will allow for the research ... University Department of Natural and Applied Sciences, Allied Health and Nursing will work ...
(Date:4/30/2016)... Rosa, CA (PRWEB) , ... April 30, 2016 , ... “Aging well is a challenge for all of us, but ... NCMA’s Dr. Parul T. Kohli . “Research is showing more and more that there ... risk of disease and disability as we age.” Top priorities Dr. Kohli’s recommends for her patients ...
(Date:4/29/2016)... Miami, FL (PRWEB) , ... April 30, 2016 ... ... manufacturer and engineer of patented products, announces the Pick Up Springboard, an automotive ... SUV and Light Truck Manufacturing industry is worth $162 billion," says Scott Cooper, ...
Breaking Medicine News(10 mins):